Lilly warned over Alimta patient booklet

Share this article:
The FDA slapped Eli Lilly with a warning letter over a patient brochure for its oncology treatment Alimta, saying the mailer glossed over the drug's indications and failed to mention its risks.

The Division of Drug Marketing, Advertising and Communications (DDMAC) letter has called the brochure misleading “because it fails to present either approved indication for Alimta.” Namely, for non-small cell lung cancer and, when used in combination with cisplatin, for mesothelioma.

In addition, DDMAC noted, the brochure provided information on types of cancers for which the drug is not indicated, “potentially creating the impression that Alimta is approved to treat a wide range of cancers”—a point the agency called “particularly concerning” because there exist approved treatments for some of the cancers covered.

DDMAC also took issue with the brochure's omission of risk information for pregnant patients, and requested that the company immediately pull the booklet.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.